Investment for Eagle Genomics
The biggest names in food, cosmetics, personal care and ‘agritech’ are looking to Eagle Genomics’ (www.eaglegenomics.com) AI-augmented, knowledge discovery platform to distil robust scientific evidence in support of marketing claims that their products have a positive biological impact.
Eagle Genomics, a pioneer in applying network science to biology – particularly linked to the microbiome – has just closed $9 million in new scale-up funding. Attracting such a high level of investment during a pandemic is testament to Eagle Genomics’ unique blend of microbiology and data science expertise, as well as its timely focus on driving powerful microbiome-related research. This is a field which is attracting the attention of global brands including Unilever, in response to huge and growing scientific interest in the role of microbes in maintaining health and wellbeing and promoting ecological renewal of the natural environment.
“We are on course to establish Eagle Genomics as a market leader at this transformative time and anchor our position as the preeminent platform vendor enabling the digital reinvention of life sciences R&D,” says Anthony Finbow, CEO at Eagle Genomics.
“The microbiome is a megatrend that is evolving very quickly, and we are the forefront of associated discovery with our unique solution to address the enterprise data challenge. We have our sights set too on other complex data challenges including CRISPR and quantum biological challenges, such as understanding the immune response more fully. The potential is phenomenal, and we are immensely grateful to our supporters for sharing our vision and helping us to scale at this pivotal time.”
Environmental Technologies Fund (ETF) and a consortium of investors from across science, AI and analytics fields have provided this latest, strategically-important round of investment which will support Eagle Genomics’ high-growth ambitions to further develop the capabilities of its powerful AI-augmented, knowledge discovery platform and to drive further commercial expansion across Europe and the US.
The consortium, led by Granpool Innovative Investments, includes bpd partners, Anatom Holding and Albert-László Barabási among others. Barabási is a world-leading network science expert, proactive investor in cutting-edge health innovation, and distinguished professor and director of Northeastern University's Center for Complex Network Research (CCNR). Previously Eagle Genomics’ investors have backed trailblazers including Finch Therapeutics, Silicon Valley microbiome innovation company Pendulum Life, and networked/personalised medicine leader Scipher Medicine.
Rob Genieser, Partner at ETF Partners (https://etfpartners.capital/), added, “We are delighted to see Eagle Genomics go from strength to strength, and to be able to support this crucial next stage of growth. The timing could not be better, with the world’s focus on disease and accelerated innovation and ever more in-silico innovation. We wish the team all the best in expanding its reach and deepening its capabilities.”
Speaking for the investor consortium, Albert-László Barabási, says “Some investment opportunities leap out, and Eagle Genomics certainly falls into that category. This is an immensely exciting science, and the appetite for the company’s unique and powerful platform is clear from the work Eagle Genomics is already doing with the likes of Unilever and the advanced discussions with some of the biggest companies in the world. I wish them all the best and will be following the company’s success with great interest.”